Aviado · Research
Longevity Daily
Wednesday, November 4, 2026
Listen
Today's Brief
Today's digest centers on a genuinely landmark finding: University of Oulu researchers show that combining a blood-pressure drug with mechanical vibration can actively flush Alzheimer's-linked proteins from the waking brain — a first for the field. A peer-reviewed University of Surrey RCT puts longevity supplement NOVOS Core on the map with three improved cardiovascular markers in healthy adults. A Japan NMN study flags the persistent gap between epigenetic clock wins and actual clinical outcomes. And a new HHS peptide policy shifts access for six compounds — without changing the evidence bar behind them.
10 stories6 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
New Treatment Flushes Dementia Proteins From the Brain — While You're Awake
Researchers at the University of Oulu have demonstrated that temporarily lowering blood pressure with medication, combined with mechanical vibration stimulation, dramatically boosts the brain's glymphatic clearance system — the network responsible for flushing out Alzheimer's-linked proteins like amyloid and tau. Critically, this 'vasomechanical' treatment works in healthy adults while they're fully awake, replicating the protein-clearance the brain normally only performs during deep sleep. This matters because people with poor sleep quality — a major Alzheimer's risk factor — have chronically compromised nighttime clearance, and no active daytime intervention existed until now. If replicated in larger clinical trials, this approach could become a standard preventive tool for anyone looking to reduce dementia risk proactively.
Read more →APOE ε4 Gene Disrupts Blood-Brain Barrier, Pointing to Three New Alzheimer's Treatment Targets
Scientists have identified how the APOE ε4 gene variant — the strongest known genetic risk factor for Alzheimer's — compromises the blood-brain barrier by allowing excess fibronectin to accumulate, triggering harmful signals that starve barrier cells of protective growth support. The discovery opens three potential intervention strategies: blocking fibronectin buildup, neutralizing the downstream harmful signals, or restoring the growth factors that keep barrier cells healthy. If you carry the APOE ε4 variant, this research points toward future therapies that could target your blood-brain barrier specifically — rather than amyloid plaques alone.
Read more →Supplements & Compounds
NOVOS Core Improves Three Key Cardiovascular Markers in Peer-Reviewed University RCT
A randomized controlled trial led by the University of Surrey and published in the European Heart Journal Open found that six months of daily NOVOS Core supplementation improved endothelial function, arterial stiffness, and systolic blood pressure in healthy middle-aged and older adults versus placebo. This is a meaningful result for a longevity supplement — most products lack peer-reviewed RCT data, let alone measured cardiovascular outcomes in humans. It's worth noting NOVOS Core contains multiple ingredients (vitamins, minerals, amino acids, and plant compounds), so isolating which components drive the effect remains an open question.
Read more →NMN Japan Study: Promising Epigenetic Age Reversal, Inconclusive on Heart and Brain
A Japanese study of a multi-ingredient NMN formulation found cardiovascular and cognitive benefits were inconclusive — but it did report a 2.79-year reversal in a functional-age composite score using the DNAm PhenoAge epigenetic clock, compared with just 0.63 years in the placebo group. This is a genuinely interesting epigenetic signal, but the study underscores the central challenge in the NMN space: biomarker shifts do not automatically translate to clinical outcomes. Take the cardiovascular and cognitive headlines with caution; take the epigenetic clock data as intriguing and worth watching in larger trials.
Read more →How Specific Probiotic Combinations Lower Liver Enzymes Through Gut Barrier Repair
Your liver health may depend more on your gut than you'd expect: when intestinal permeability increases, inflammatory molecules leak into the bloodstream and stress the liver, raising enzymes like ALT and AST. Across multiple large-scale studies involving over 2,000 people with fatty liver, diabetes, or metabolic issues, three-strain probiotic combinations (Lactobacillus, Bifidobacterium, and Streptococcus) reduced liver enzymes by 7–10 IU/L within 8–12 weeks by repairing the gut barrier and lowering zonulin — and single-strain products consistently underperformed. This gut-liver mechanism works whether you have elevated markers now or are simply trying to prevent future liver stress.
Read the full Aviado analysis →Research & Papers
Here's the Aerobic Fitness Threshold Linked to Slower Biological Aging in Older Men
Japanese researchers measured peak aerobic capacity in 144 men aged 65–72 and compared it against DunedinPACE, a gold-standard DNA methylation clock that tracks the pace of biological aging — finding that men with VO2peak above 26 mL/kg/min showed a measurably slower rate of aging, an association that held after controlling for age, smoking, and alcohol. The study is observational and male-only, limiting generalizability, but it offers health-conscious readers a specific, testable benchmark. If your VO2 max sits below 26, structured cardio training may be one of your highest-leverage anti-aging investments right now.
Read more →Three-Day Senolytic Course Reversed Liver Disease in Half of Trial Participants in Their 60s
Senolytic compounds — drugs that selectively destroy 'zombie' senescent cells — are showing early human clinical promise, with one trial finding that a brief three-day course reversed measurable liver disease outcomes in roughly half of participants in their 60s within weeks. The underlying mechanism is well-characterized: clearing senescent cells reduces the chronic inflammatory signaling (SASP) that drives tissue damage across organs including the liver. Sample sizes remain small and larger confirmatory trials are needed, but this is one of the clearest human signals yet that senolytics can produce real clinical change — not just biomarker shifts in mice.
Read more →Lifestyle & Nutrition
Green Tea Compound EGCG Linked to Lower Biological Age in Nearly 11,000 Adults
An analysis of nearly 11,000 adults found that people who consumed EGCG — the primary active polyphenol in green tea — had lower biological aging scores, reduced risk of death during the study's follow-up period, and a longer estimated remaining lifespan compared to those who consumed none. The effect was dose-graded and held across dietary sources, suggesting you don't need supplements: a few cups of green tea daily appear sufficient to register a signal. This is observational data and cannot prove causation, but the effect sizes and consistency across a large, diverse sample make it a compelling lifestyle finding worth acting on.
Read more →Metformin Taken Within a Week of COVID-19 Diagnosis Cuts Long COVID and Death Risk by 53%
A study published in the Journal of Medical Virology found that COVID-19 patients prescribed metformin within six days of diagnosis were 53% less likely to develop long COVID or die compared to those who weren't. This builds on RCT-level evidence from the TOGETHER trial pointing to metformin as a cheap, widely available intervention with meaningful post-infection benefits — not just blood sugar control. For anyone at risk of COVID-19 exposure, this study is a strong reason to discuss early metformin use with your doctor, particularly given its established safety record and low cost.
Read more →Industry & Policy
Six Peptides Just Got a Compounding Pathway — Here's What That Actually Means
A new HHS draft policy creates a conditional route for compounding pharmacies to dispense six previously restricted peptides popular in the longevity and performance community, including BPC-157. As one physician-author makes clear: access, evidence, and FDA approval are three entirely different things — a compounding pathway does not mean the FDA has reviewed or endorsed these compounds for safety or efficacy. If you've been waiting for easier legal access to compounding peptides, this policy shift is real; if you're weighing the safety question, the evidence bar has not moved.
Read more →